Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $41

Benzinga · 2d ago
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $58 to $41.